Alectinib is specifically indicated for patients with ALK-positive NSCLC. ALK-positive status is determined through diagnostic testing, usually involving biopsy samples. This targeted therapy is most beneficial for patients who have developed resistance to other treatments or who have experienced a recurrence of cancer.
